Every night, the online Belgian patent register ('eRegister') receives an update with public data that were entered or generated the preceding day on the Benelux Patent Platform, the computer application with which the Belgian Intellectual Property Office handles the registration, treatment and publication processes for patents and supplementary protection certificates.
Currently, some updates are spread over consecutive nights due to the large, weekly volume of data concerning European patents designating Belgium.
For a European patent it is possible that data about the inventor(s) are missing from the online Belgian patent register. They can be found via the link to the European patent register pending an update of the Belgian patent register.
For European patents with Unitary Effect, the authentic source of information is the European Patent Register : please refer to it.

Patent details

2521543 Title: ASSOCIATION D'UN COMPOSÉ IMMUNOMODULATEUR ET D'UNE DÉRIVÉ D'ARTÉMISININE POUR LE TRAITEMENT DU CANCER

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic information

Application number:
117002881
WO application number:
US2011020160
Type:
European patent granted for BE
Status:
Deemed Void
Publication number:
2521543
WO publication number:
WO2011084968
1rst applicant's nationality:
Translation language:
EPO publication language:
English
SPC number:

Dates

Filing date:
05/01/2011
Grant date:
13/04/2016
EP publication date:
14/11/2012
WO publication date:
14/07/2011
Claims translation received date:
Translation received date (EP publication B1):
Translation received date (EP publication B2):
Translation received date (EP publication B3):
Registration date:
13/04/0002
EP B1 publication date:
13/04/2016
EP B2 publication date:
EP B3 publication date:
Lapsed date:
Expiration date (if granted and all annual fees paid):
05/01/2031

Applicant

Name:
Celgene Corporation
Legal Form:
From:
13/04/2016
Address:
86 Morris Avenue, Summit, NJ 07901, United States (US)
To:

Inventor

1

Name:
DALGLEISH, Angus
Legal Form:
Address:
Cheam Surrey SM2 7PP, United Kingdom (GB)

2

Name:
GRAVETT, Andrew
Legal Form:
Address:
London SW19 1AA, United Kingdom (GB)

3

Name:
LIU, Wai
Legal Form:
Address:
Old Coulsdon Surry CR5 1QS, United Kingdom (GB)

Priority

1

Priority patent number:
371347 P
Priority date:
06/08/2010
Priority country:
United States (US)

2

Priority patent number:
292307 P
Priority date:
05/01/2010
Priority country:
United States (US)

Classification

IPC or IDT classification:
A61K 31/454; A61K 31/282; A61K 31/357; A61K 31/366; A61K 31/4035; A61K 31/541; A61K 31/7068; A61K 45/06; A61P 35/00;

Publication

European Patent Bulletin

Issue number:
201615
Publication date:
13/04/2016
Description:
Grant (B1)

Annual fee

Annual fee(s) Due Date:
31/01/2017
Annual fee number:
7
Annual fee amount:
110 Euro
Expected payer:
Last annual fee payment date:
Last annual fee paid number:
Payer:
Filing date Document type Publication Type Document Description Number of pages File Type